Authors
Alanoud Al Shmarri, Duha Marwan Naji, Elmustafa Abdalla, Abdulrahman F Al-Mashdali, Mohammed Ahmed, V-Ayah Elhadi, Deena Mudawi, Mohammad Abdulgayoom, Imran Ahmad, Samah Kohla, Sarah Elkourashy, Shehab F Mohamed
Published in
SAGE open medical case reports. Volume 14. Pages 2050313X251412704. Epub Aug 07, 2026.
Abstract
Pure red cell aplasia is a rare hematologic disorder characterized by severe normocytic anemia, reticulocytopenia, and absence of erythroid precursors. Since the COVID-19 pandemic, pure red cell aplasia has emerged as an uncommon post-infectious complication, likely driven by immune dysregulation. A 72-year-old man developed transfusion-dependent anemia several weeks after a mild COVID-19 infection. Laboratory evaluation revealed normocytic anemia (hemoglobin of 7.0 g/dL) with profound reticulocytopenia, and bone marrow biopsy showed markedly reduced erythropoiesis with preserved granulopoiesis and megakaryopoiesis. Secondary causes, including nutritional deficiencies, hemolysis, autoimmune disease, parvovirus B19, and hematologic malignancy, were excluded. The patient failed to respond to intravenous immunoglobulin, corticosteroids, and cyclosporine, achieving only a transient partial remission. Rituximab therapy was subsequently initiated and resulted in complete hematologic recovery and sustained remission at 1 year. COVID-19-associated pure red cell aplasia is a rare but clinically important complication. Clinicians should consider it in patients with severe post-COVID anemia, and rituximab may be effective in cases refractory to standard immunosuppressive therapy.
PMID:
42571205
Bibliographic data and abstract were imported from PubMed on 09 Aug 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 6
- Comments 0